$-0.40
(Market cap
$36 Mln
Revenue (TTM)
$15 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-9.4
-
Face value
--
-
Shares outstanding
6,738,545
6 Years Aggregate
CFO
$-385.62 Mln
EBITDA
$-558.99 Mln
Net Profit
$-546.01 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Generation Bio Co (GBIO)
| -6.0 | -2.6 | 4.5 | -29.7 | -54.1 | -56.1 | -- |
|
BSE Sensex*
| -9.1 | -1.2 | 2.9 | -3.6 | 5.7 | 6.2 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Generation Bio Co (GBIO)
| -46.4 | -35.5 | -58.0 | -44.5 | -75.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Generation Bio Co (GBIO)
|
5.3 | 36.0 | 15.3 | -62.6 | -414.9 | -101.1 | -- | 0.7 |
| 38.6 | 3,703.2 | 586.5 | -106.4 | -16.6 | -- | -- | 5.3 | |
| 15.5 | 1,820.1 | 330.5 | -43.4 | -10.3 | -8.1 | -- | 3.3 |
Shareholding Pattern
View DetailsAbout Generation Bio Co (GBIO)
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid... nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Read more
-
President, CEO & Director
Dr. Cameron Geoffrey McDonough M.D.
-
President, CEO & Director
Dr. Cameron Geoffrey McDonough M.D.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Generation Bio Co (GBIO)
What is the current share price of Generation Bio Co (GBIO) Today?
The share price of Generation Bio Co (GBIO) is $5.34 (NASDAQ) as of 10-Feb-2026 09:30 EDT. Generation Bio Co (GBIO) has given a return of -54.09% in the last 3 years.
What is the current PB & PE ratio of Generation Bio Co (GBIO)?
Since, TTM earnings of Generation Bio Co (GBIO) is negative, P/E ratio is not available.
The P/B ratio of Generation Bio Co (GBIO) is 0.71 times as on 10-Feb-2026, a 86 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-0.05 |
0.08 |
2023 |
-0.84 |
0.52 |
2022 |
-0.18 |
0.08 |
2021 |
-0.35 |
0.11 |
2020 |
-1.70 |
0.49 |
What is the 52 Week High and Low of Generation Bio Co (GBIO)?
The 52-week high and low of Generation Bio Co (GBIO) are Rs 7.60 and Rs 3.00 as of 31-Aug-2026.
What is the market cap of Generation Bio Co (GBIO)?
Generation Bio Co (GBIO) has a market capitalisation of $ 36 Mln as on 10-Feb-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Generation Bio Co (GBIO)?
Before investing in Generation Bio Co (GBIO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.